Selçuklu Holding
İlko İlaç Sanayi ve Ticaret A.Ş

The current representative of more than 50 years of knowledge in the Turkish pharmaceutical industry...

We research and develop
for your health.

A new investment, launched as ILKO Ilaç San. ve Tic. A.Ş., has been underway since 2009 in the national and international markets to capitalize upon long years of experience in the pharmaceutical industry as the first line of business within the body of Selçuklu Holding.

Founded in Konya based on the principle that the most important two factors for effective in the pharmaceutical industry are a strong R&D and a strong production, ILKO Pharmaceuticals Production Facilities is the largest pharmaceutical production investment in Anatolia. The facility founded on an area of 250,000sqm has an indoor area of 25,000sqm. The annual production capacity of the main facility is planned as 120 million boxes.

ILKO Pharmaceuticals , which attaches great importance and allocates great resource to R&D, continues its R&D operations at ILKO Research & Development Center founded in Hacettepe University Technocity in 2009. ILKO Argem that happens to be a pioneer and exemplary R&D investment at this scale established within the body of Technocity as an university - industry cooperation in Turkey has an indoor area of 2600sqm.

ILKO Pharmaceuticals that founded ILKO Argem Biotechnology within the body of Technocity Istanbul in 2015 continues its R&D operations regarding biotechnology products at this center. ILKO Argem Biotechnology Center has an infrastructure that will enable production of biosimilar, biobetter and new generation drugs.

Equipped with the required infrastructure to provide service in all acute and chronic treatment areas, ILKO Pharmaceuticals’s portfolio includes primarily drugs for central and peripheral nervous system diseases, gastrointestinal system diseases, cardiovascular diseases, antibiotics, asthma, allergic rhinitis and urticaria treatment.

ILKO Pharmaceuticals ranked first in Turkey in 2013 and has taken a step to make Turkey a player in the biotechnology market. This was a widely accepted goal for the future of the global pharmaceutical industry by founding ILKOGEN companion together with Genexine, a South Korean biotechnology firm. ILKOGEN is the first biotechnology pharmaceutical R&D, production and international marketing investment of Turkey.

On the other hand, ILKO Pharmaceuticals created Wellcare brand to generate right solutions to the new emerged needs and bring a new breath to the Consumer Health field within the framework of his approach to handle Consumer Health as a whole. Wellcare aims to offer solutions to health problems and raise the quality of life at every stage of life as of birth with its innovative, clinically-proven, scientific and reliable, after-care treatment products that are approved by health authorities in 6 different categories: Baby Health, Digestive Health, Probiotics, Allergy, Vitamins and Minerals, Cold and Cough.

With all its production and R&D investments, ILKO Pharmaceuticals aims to carry Turkey to a different position in the global competition.

Selin Yapı